NEW YORK (360Dx) – Swedish blood test developer AroCell announced today it will collaborate with Green Cross Cell to develop TK 210 ELISA as a complementary test for the Korean firm's therapeutic products and methods.
The agreement also gives Green Cross Cell distribution rights to the test.
The TK 210 ELISA test measures TK1 protein levels in cancer patients, potentially providing prognostic information, as well as optimizing treatment strategies.
Green Cross Cell acquired the product license of an anticancer immunotherapy product for liver cancer in 2007 and is developing immunotherapies with a focus on liver, colorectal, and glioblastoma brain cancer.
"We are very excited about this collaboration with Green Cross Cell, not only the distribution of our product but also the plan to use TK 210 ELISA as their primary biomarker for their therapeutic drugs and treatments," AroCell CEO Jan Stålemark CEO said in a statement.
Financial and other terms of the deal were not disclosed.
AroCell develops blood tests for determining the prognosis of patients with cancer and aid in their follow-up care. TK 210 ELISA helps clinicians to determine the best treatments for their patients and to evaluate the risk of disease recurrence, the firm said.